CareDx, Inc. (CDNA)

CareDx's stock has been impacted by several events including a Q3 2025 earnings beat, a proposed Medicare coverage change that caused a stock plummet, CEO stock sales, and a stock buyback program. The company reported revenue growth and maintained financial stability, with the stock experiencing a 52-week range between $10.96 and $25.95.

Information detailing demand seasonality for CareDx's products is not explicitly available. Demand is likely driven by the ongoing need for organ transplants and continuous patient monitoring, rather than seasonal fluctuations. The increasing prevalence of chronic diseases and advancements in transplant procedures are noted as trends driving the demand for transplant diagnostic tools.

CareDx, Inc. is a precision medicine company focused on developing and commercializing healthcare solutions for transplant patients. It operates in the Healthcare sector, specifically in Medical - Diagnostics & Research and Biotechnology. The company offers testing services like AlloSure Kidney, AlloMap Heart, and digital solutions such as Ottr and AlloCare.

CareDx generates most of its revenue from the United States but has a significant international presence, offering its diagnostic solutions globally.

CareDx is recognized as a leading provider of transplant-focused solutions. Events affecting its reputation include a proposed Medicare coverage change, CEO and insider stock sales, and the acquisition of MediGO, which expanded its digital health portfolio.

CareDx, Inc. has a significant institutional ownership base, with major holders including BlackRock, Inc. and Vanguard Group Inc. Neil Gagnon is a significant individual insider shareholder, owning 12.44% of the company.